Capsule Summary Slidesets

Share

Program Content

Activities

  • DESTINY-CRC01
    Phase II DESTINY-CRC01: Trastuzumab Deruxtecan in Patients With HER2-Expressing Metastatic Colorectal Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 01, 2020

    Expires: May 31, 2021

  • PRODIGE 23
    PRODIGE 23: Phase III Trial of Neoadjuvant mFOLFIRINOX Plus CRT vs Preoperative CRT in Locally Advanced Rectal Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2020

    Expires: June 04, 2021

  • RTOG 1010
    Phase III RTOG 1010: Addition of Trastuzumab to Trimodality Treatment in Resectable HER2-Positive Esophageal Adenocarcinoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 02, 2020

    Expires: June 01, 2021

  • SWOG S1505
    SWOG S1505: Phase II Study of Perioperative CT With mFOLFIRINOX vs Gemcitabine/nab-Paclitaxel in Resectable Pancreatic Ductal Adenocarcinoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 04, 2020

    Expires: June 03, 2021

  • DESTINY-Gastric01
    DESTINY-Gastric01: Trastuzumab Deruxtecan in Previously Treated, HER2+ Advanced Gastric or GEJ Adenocarcinoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 01, 2020

    Expires: May 31, 2021

  • KEYNOTE-177
    KEYNOTE-177: Phase III Trial of First-line Pembrolizumab vs Chemotherapy in MSI-H/dMMR Metastatic CRC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 04, 2020

    Expires: June 03, 2021

Provided by

ProCE Banner

Supporters

AbbVie Inc.

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Jazz Pharmaceuticals

Karyopharm Therapeutics

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer and EMD Serono